Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Tai-Lung Cha,1,2*
Binhua P. Zhou,1
Weiya Xia,1
Yadi Wu,1
Cheng-Chieh Yang,1,2
Chun-Te Chen,1
Bo Ping,1
Arie P. Otte,3
Mien-Chie Hung1,2
Abstract:
Enhancer of Zeste homolog 2 (EZH2) is a methyltransferase thatplays an important role in many biological processes throughits ability to trimethylate lysine 27 in histone H3. Here, weshow that Akt phosphorylates EZH2 at serine 21 and suppressesits methyltransferase activity by impeding EZH2 binding to histoneH3, which results in a decrease of lysine 27 trimethylationand derepression of silenced genes. Our results imply that Aktregulates the methylation activity, through phosphorylationof EZH2, which may contribute to oncogenesis.
1 Department of Molecular and Cellular Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. 2 Graduate School of Biomedical Sciences, the University of Texas Health Science Center at Houston, Houston, TX 77030, USA. 3 Swammerdam Institute for Life Sciences, University of Amsterdam, Kruislaan 406, 1098 SM Amsterdam, the Netherlands.
* Present address: Division of Urology, Department of Surgery,Tri-Service General Hospital, National Defense Medical Center,National Defense University, Taipei, 104, Taiwan.
Present address: Sealy Center for Cancer Cell Biology, the Universityof Texas Medical Branch, Galveston, TX 775551048, USA.
To whom correspondence should be addressed. E-mail: mhung{at}mdanderson.org
The editors suggest the following Related Resources on Science sites:
NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes.
N. Minnebo, J. Gornemann, N. O'Connell, N. Van Dessel, R. Derua, M. W. Vermunt, R. Page, M. Beullens, W. Peti, A. Van Eynde, et al. (2013)
Nucleic Acids Res.
41, 842-854
|Abstract »|Full Text »|PDF »
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent.
K. Xu, Z. J. Wu, A. C. Groner, H. H. He, C. Cai, R. T. Lis, X. Wu, E. C. Stack, M. Loda, T. Liu, et al. (2012)
Science
338, 1465-1469
|Abstract »|Full Text »|PDF »
Y. Liu, D.-L. Wang, S. Chen, L. Zhao, and F.-L. Sun (2012)
J. Biol. Chem.
287, 41469-41480
|Abstract »|Full Text »|PDF »
Akt Phosphorylates the Transcriptional Repressor Bmi1 to Block Its Effects on the Tumor-Suppressing Ink4a-Arf Locus.
Y. Liu, F. Liu, H. Yu, X. Zhao, G. Sashida, A. Deblasio, M. Harr, Q.-B. She, Z. Chen, H.-K. Lin, et al. (2012)
Science Signaling
5, ra77
|Abstract »|Full Text »|PDF »
Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor-Propagating Cells in Prostate Cancer.
H. Cai, S. Memarzadeh, T. Stoyanova, Z. Beharry, A. S. Kraft, and O. N. Witte (2012)
Cancer Res.
72, 4672-4681
|Abstract »|Full Text »|PDF »
Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia.
M. Trost, M. Sauvageau, O. Herault, P. Deleris, C. Pomies, J. Chagraoui, N. Mayotte, S. Meloche, G. Sauvageau, and P. Thibault (2012)
Blood
120, e17-e27
|Abstract »|Full Text »|PDF »
Regulation of A Disintegrin And Metalloprotease-33 Expression by Transforming Growth Factor-{beta}.
Y. Yang, J. Wicks, H. M. Haitchi, R. M. Powell, W. Manuyakorn, P. H. Howarth, S. T. Holgate, and D. E. Davies (2012) 46, 633-640
|Abstract »|Full Text »|PDF »
Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis.
K. L. Greathouse, T. Bredfeldt, J. I. Everitt, K. Lin, T. Berry, K. Kannan, M. L. Mittelstadt, S.-m. Ho, and C. L. Walker (2012)
Mol. Cancer Res.
10, 546-557
|Abstract »|Full Text »|PDF »
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
D. T. Worster, T. Schmelzle, N. L. Solimini, E. S. Lightcap, B. Millard, G. B. Mills, J. S. Brugge, and J. G. Albeck (2012)
Science Signaling
5, ra19
|Abstract »|Full Text »|PDF »
When Silence is Broken: Polycomb Group Proteins in Heart Development.
G. Dobreva and T. Braun (2012)
Circ. Res.
110, 372-374
|Full Text »|PDF »
Evidence for Alteration of EZH2, BMI1, and KDM6A and Epigenetic Reprogramming in Human Papillomavirus Type 16 E6/E7-Expressing Keratinocytes.
P. L. Hyland, S. S. McDade, R. McCloskey, G. J. Dickson, K. Arthur, D. J. McCance, and D. Patel (2011)
J. Virol.
85, 10999-11006
|Abstract »|Full Text »|PDF »
Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability.
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells.
Lung-Cancer Chemoprevention by Induction of Synthetic Lethality in Mutant KRAS Premalignant Cells In Vitro and In Vivo.
S. Huang, X. Ren, L. Wang, L. Zhang, and X. Wu (2011)
Cancer Prevention Research
4, 666-673
|Abstract »|Full Text »|PDF »
Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
D. Sasaki, Y. Imaizumi, H. Hasegawa, A. Osaka, K. Tsukasaki, Y. L. Choi, H. Mano, V. E. Marquez, T. Hayashi, K. Yanagihara, et al. (2011)
Haematologica
96, 712-719
|Abstract »|Full Text »|PDF »
Chromatin in the Nuclear Landscape.
D. B. Beck, R. Bonasio, S. Kaneko, G. Li, G. Li, R. Margueron, H. Oda, K. Sarma, R. J. Sims III, J. Son, et al. (2011)
Cold Spring Harb Symp Quant Biol
|Abstract »|PDF »
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
S. Zheng, E. A. Houseman, Z. Morrison, M. R. Wrensch, J. S. Patoka, C. Ramos, D. A. Haas-Kogan, S. McBride, C. J. Marsit, B. C. Christensen, et al. (2011)
Neuro Oncology
13, 280-289
|Abstract »|Full Text »|PDF »
Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer.
T. Zuo, T.-M. Liu, X. Lan, Y.-I. Weng, R. Shen, F. Gu, Y.-W. Huang, S. Liyanarachchi, D. E. Deatherage, P.-Y. Hsu, et al. (2011)
Cancer Res.
71, 1752-1762
|Abstract »|Full Text »|PDF »
Rapid activation of the bivalent gene Sox21 requires displacement of multiple layers of gene-silencing machinery.
H. Chakravarthy, B. D. Ormsbee, S. K. Mallanna, and A. Rizzino (2011)
FASEB J
25, 206-218
|Abstract »|Full Text »|PDF »
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA.
S. Kaneko, G. Li, J. Son, C.-F. Xu, R. Margueron, T. A. Neubert, and D. Reinberg (2010)
Genes & Dev.
24, 2615-2620
|Abstract »|Full Text »|PDF »
The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets.
N. Van Dessel, L. Beke, J. Gornemann, N. Minnebo, M. Beullens, N. Tanuma, H. Shima, A. Van Eynde, and M. Bollen (2010)
Nucleic Acids Res.
38, 7500-7512
|Abstract »|Full Text »|PDF »
The T-loop Extension of the Tomato Protein Kinase AvrPto-dependent Pto-interacting Protein 3 (Adi3) Directs Nuclear Localization for Suppression of Plant Cell Death.
M. J. Ek-Ramos, J. Avila, C. Cheng, G. B. Martin, and T. P. Devarenne (2010)
J. Biol. Chem.
285, 17584-17594
|Abstract »|Full Text »|PDF »
Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.
M. J. Kwon, S.-S. Kim, Y.-L. Choi, H. S. Jung, C. Balch, S.-H. Kim, Y.-S. Song, V. E. Marquez, K. P. Nephew, and Y. K. Shin (2010)
Carcinogenesis
31, 974-983
|Abstract »|Full Text »|PDF »
Xenoestrogen-Induced Regulation of EZH2 and Histone Methylation via Estrogen Receptor Signaling to PI3K/AKT.
T. G. Bredfeldt, K. L. Greathouse, S. H. Safe, M. C. Hung, M. T. Bedford, and C. L. Walker (2010)
Mol. Endocrinol.
24, 993-1006
|Abstract »|Full Text »|PDF »
Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma.
B. M. Costa, J. S. Smith, Y. Chen, J. Chen, H. S. Phillips, K. D. Aldape, G. Zardo, J. Nigro, C. D. James, J. Fridlyand, et al. (2010)
Cancer Res.
70, 453-462
|Abstract »|Full Text »|PDF »
Hyperactivated NF-{kappa}B and AP-1 Transcription Factors Promote Highly Accessible Chromatin and Constitutive Transcription across the Interleukin-6 Gene Promoter in Metastatic Breast Cancer Cells.
M. N. Ndlovu, C. Van Lint, K. Van Wesemael, P. Callebert, D. Chalbos, G. Haegeman, and W. Vanden Berghe (2009)
Mol. Cell. Biol.
29, 5488-5504
|Abstract »|Full Text »|PDF »
Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line.
B. D.W. Karanikolas, M. L. Figueiredo, and L. Wu (2009)
Mol. Cancer Res.
7, 1456-1465
|Abstract »|Full Text »|PDF »
Alterations of histone modifications by cobalt compounds.
PRDM5 Identified as a Target of Epigenetic Silencing in Colorectal and Gastric Cancer.
Y. Watanabe, M. Toyota, Y. Kondo, H. Suzuki, T. Imai, M. Ohe-Toyota, R. Maruyama, M. Nojima, Y. Sasaki, Y. Sekido, et al. (2007)
Clin. Cancer Res.
13, 4786-4794
|Abstract »|Full Text »|PDF »
Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1.
K. Higashimoto, P. Kuhn, D. Desai, X. Cheng, and W. Xu (2007)
PNAS
104, 12318-12323
|Abstract »|Full Text »|PDF »
Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma.
C. Lu, T. Bonome, Y. Li, A. A. Kamat, L. Y. Han, R. Schmandt, R. L. Coleman, D. M. Gershenson, R. B. Jaffe, M. J. Birrer, et al. (2007)
Cancer Res.
67, 1757-1768
|Abstract »|Full Text »|PDF »
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases.
M. A. Bogoyevitch and B. Kobe (2006)
Microbiol. Mol. Biol. Rev.
70, 1061-1095
|Abstract »|Full Text »|PDF »
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, A. Chinnaiyan, P. Atadja, and K. Bhalla (2006)
Mol. Cancer Ther.
5, 3096-3104
|Abstract »|Full Text »|PDF »
Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells.
P. H. Abbosh, J. S. Montgomery, J. A. Starkey, M. Novotny, E. G. Zuhowski, M. J. Egorin, A. P. Moseman, A. Golas, K. M. Brannon, C. Balch, et al. (2006)
Cancer Res.
66, 5582-5591
|Abstract »|Full Text »|PDF »